<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82390">
  <stage>Registered</stage>
  <submitdate>1/11/2007</submitdate>
  <approvaldate>9/11/2007</approvaldate>
  <actrnumber>ACTRN12607000578404</actrnumber>
  <trial_identification>
    <studytitle>Coronary Intervention Using the CardioMind Coronary Stent System for the treatment of stenotic lesions in small diameter native coronary arteries</studytitle>
    <scientifictitle>A prospective, randomized, multicenter study to evaluate the safety, efficacy and performance of the CardioMind Coronary Stent Systems for treatment of stenotic lesions in small diameter native coronary arteries.</scientifictitle>
    <utrn />
    <trialacronym>CARE II</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary artery disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study will randomize 230 patients with de novo lesions in native coronary arteries with a reference diameter of 2.0  2.75 mm. The 3 treatment arms include the CardioMind sirolimus-eluting stent, the CardioMind bare metal stent, and the Medtronic Micro-Driver bare metal stent. Clinical follow-up will occur at 30 days, 8, 12 and 24 months. Telephone follow-up will occur at 6 months and years 3-5. Data will be compared among treatment groups.</interventions>
    <comparator>Medtronic Micro-Driver bare metal stent for the same duration of the intervention</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>In-stent late lumen loss by quantitative  coronary angiography (QCA)</outcome>
      <timepoint>8 months after treatment]</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major adverse cardiac events</outcome>
      <timepoint>Hospital discharge, 30 days, 8, 12, 24 months after treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major vascular complications</outcome>
      <timepoint>hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Stent thrombosis</outcome>
      <timepoint>Within 30 days after treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device, Lesion, Procedure Success</outcome>
      <timepoint>Hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically driven target lesion revascularization, target vessel revascularization or target vessel failure</outcome>
      <timepoint>30 days, 8, 12, 24 months after treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-stent and in-segment binary restenosis, minimum lumen diameter and % diameter stenosis</outcome>
      <timepoint>8 months after treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-segment late lumen loss</outcome>
      <timepoint>8 months after treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2D &amp; 3D Intravascular Ultrasound (sub-set of patients)</outcome>
      <timepoint>8 months after treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Suitable candidate for percutaneous coronary intervention (PCI) in a symptomatic native coronary vessel with a reference diameter of 2.0  2.75 mm and lesion length &lt; 20 mm. Treatment of one non-target lesion in a separate epicardial vessel is allowed.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Need for treatment of a second lesion in the target vessel 30 days before or after the index procedure, excessive calcification or tortuosity, presence of thrombus or Thrombolysis in Myocardial Infarction (TIMI) flow &lt; 2, concomitant health conditions (renal insufficiency, recent stroke, myocardial infarction (MI) or gastrointestinal (GI) bleeding), pregnant, unable to comply with antiplatelet therapy, ostial lesions, low coronary reserve.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After angiographic criteria is confirmed, the investigator will open a sequentially numbered envelope containing a randomization assignment card for that subject.</concealment>
    <sequence>Subjects will be block-randomized by clinical site.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>230</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3065</postcode>
    <postcode>3168</postcode>
    <postcode>4032</postcode>
    <postcode>5000</postcode>
    <postcode>3000</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brazil
Germany
Switzerland
New Zealand
Spain
Singapore
Malaysia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CardioMind</primarysponsorname>
    <primarysponsoraddress>257 Humboldt Court
Sunnyvale, CA 94089</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>CardioMind</fundingname>
      <fundingaddress>257 Humboldt Court
Sunnyvale, CA 94089</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will enroll 230 patients in a randomized evaluation of a new stent delivery system developed for use in small coronary arteries. The study device is designed with a low profile, maneuverable delivery system to reach small, distal lesions. This study is designed to show that the new stents are safe and effective when compared to the comparator, commercially-available stent. Follow-up will occur at 30 days, 6, 8, and 12 month intervals for the first year, then annually for the next four years.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. Vincent's Health</ethicname>
      <ethicaddress>140 Williams St.
Melbourne VIC 3000
PO Box 4301PP
Melbourne VIC 3001
Australia</ethicaddress>
      <ethicapprovaldate>18/10/2007</ethicapprovaldate>
      <hrec>MIR:AZR:0431861</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Marlys Kaluzniak</name>
      <address>257 Humboldt Court
Sunnyvale, CA 94089</address>
      <phone>+1 805-990-1646</phone>
      <fax>+1 408 329 5252</fax>
      <email>mkaluzniak@cardiomind.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Marlys Kaluzniak</name>
      <address>257 Humboldt Court
Sunnyvale, CA 94089</address>
      <phone>+1 805-990-1646</phone>
      <fax>+1 408 329 5252</fax>
      <email>mkaluzniak@cardiomind.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Marlys Kaluzniak</name>
      <address>257 Humboldt Court
Sunnyvale, CA 94089</address>
      <phone>805-990-1646</phone>
      <fax>+1 408 329 5252</fax>
      <email>mkaluzniak@cardiomind.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>